The peptides tag is a catch-all for stories that cut across drug classes — peptide chemistry, manufacturing, the broader research-peptide market, and the policy questions that shape access.
Recurring threads: peptide CDMO capacity (Bachem, PolyPeptide, BASF) and how it became the GLP-1 bottleneck; AI-driven peptide discovery using de novo design, protein language models, and transformer architectures; macrocyclic and bicyclic peptide chemistry as the route to undruggable targets; peptide-drug conjugates as the next ADC wave; the unregulated grey-market peptide economy and its safety implications; and venom-derived peptides moving toward clinical use.
If the story is about peptides as a class — chemistry, manufacturing, policy, the field's direction — it lives here. For specific peptides, drugs, or companies, follow the dedicated tags.
The Washington Post framed the FDA's upcoming July peptide panel through the lens of the exploding wellness craze, noting peptides are pitched as quick fixes for muscle building, injury healing, and anti-aging with minimal supporting research. When the FDA added 19 peptides to its restricted list in 2023, it cited safety risks including cancer and liver, kidney, and heart problems — concerns that have not been resolved.
CNN published a comprehensive consumer guide distinguishing FDA-approved peptide therapeutics from unregulated wellness peptides. Experts warn that rising demand is fueling an online black market with unknown safety risks, while HHS Secretary RFK Jr. pushes to relax restrictions.
CBC investigation compares the peptide trend to historical pseudoscience, with scientists emphasizing no large-scale human trials exist for peptides sold by influencers.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
Hims & Hers stock briefly rallied on reports the FDA may ease peptide restrictions, but gains reversed. The company had proactively acquired a peptide production facility in California in 2025.
Digital health companies are betting on peptides as the next big wellness category. They're banking on HHS Secretary RFK Jr. getting the FDA to lift restrictions on certain peptides.
Hims & Hers Health stock rose on reports the FDA is preparing to allow compounding pharmacies to produce previously banned injectable peptides, potentially expanding the telehealth company's operations.
Federal regulators are moving toward restoring legal access to injectable peptides barred from pharmacy compounding in 2023, which could redirect patients from unregulated online sellers to regulated pharmacy channels.
STAT's pharmaceutical roundup covers the FDA's expected move to allow compounding of previously banned peptides and the impact of the Iran conflict on global clinical trial recruitment.
The FDA is moving to allow compounding pharmacies to produce 14+ injectable peptides banned in 2023. Health Secretary RFK Jr. publicly backed the reversal, while top FDA leaders reportedly have reservations about politically-driven decisions.
Longevity enthusiasts anticipate FDA loosening restrictions on BPC-157, ipamorelin, and MOTs-C. Industry notes it may take months for compounding pharmacies to ramp up supply after reclassification.
Eric Topol of Scripps Research called peptide data "woefully minuscule," warning about impurities, random dosing, and dangerous stacking of unproven compounds from gray-market sources.
In-depth AP investigation on influencers and celebrities promoting unapproved injectable peptides produced by compounding pharmacies without FDA-level scrutiny.
The FDA held a public meeting to discuss broadening supplement ingredient criteria to include peptides, probiotics, and other substances. This is the first such meeting since RFK Jr. became HHS Secretary.
Report examining viral social media claims about peptides promising DNA repair, nerve relief, and wound healing, referencing RFK Jr.'s Joe Rogan appearance supporting peptide access.
Companies are rushing to upgrade from gray-market research-grade to medical-grade peptide standards to supply doctors' offices as deregulation approaches.
CBS warns that viral peptide claims on social media far outpace clinical evidence, with 60% of 10.1M monthly searches related to GLP-1 drugs and many trending peptides lacking FDA approval.
Investigative journalist documents how consumers buy injectable peptides from Chinese factories via social media and Reddit. The global peptide market has swelled to $50 billion annually.